What Behind the Jaw-Dropping 556% Rally in Bolt Projects Stock (BSLK)?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
What Does Bolt Projects Holdings Do?
Bolt Projects is a biomaterials company that creates innovative solutions for the beauty and personal care industry. Its Vegan Silk Technology Platform creates eco-friendly silk alternatives from plant-based or bio-engineered sources rather than silkworms.
Bolt Projects Reports Massive Sales Growth
In Q2, Bolt Projects' revenue soared more than 2,200% year-over-year to $1.3 million. The company also narrowed its net loss to $4.6 million, a sharp improvement from the $58.9 million loss reported a year ago.
Additionally, Bolt achieved a positive gross margin, posting a gross profit of $62,000 versus a $29,000 gross loss in the same quarter last year.
What Lies Ahead for Bolt Projects?
Bolt Projects' recent growth has been fueled largely by surging demand for its Vegan Silk Technology Platform. CEO Dan Widmaier stated that the platform offers high-performance, eco-friendly benefits that meet customer needs and set the company up for long-term growth.
Bolt's Vegan Silk is already attracting interest from major beauty players. A global skincare brand, owned by one of the world's top seven beauty conglomerates, plans to launch its first product featuring Vegan Silk in 2026, with additional products already in the pipeline. Such partnerships signal a growing shift in the industry toward sustainable ingredients, where Bolt has a clear competitive advantage.
Looking ahead, Bolt has, for the first time, added gross profit projections to its financial guidance. The company expects at least $500,000 in gross profit in 2025 and $1 million in 2026, alongside minimum revenue targets of $4.5 million and $9 million, respectively. If Vegan Silk adoption continues to accelerate, these numbers could mark just the beginning of Bolt's growth trajectory.
Is BSLK a Good Stock to Buy?
Turning to Wall Street, analysts have a Hold consensus rating on BSLK stock based on one Hold recommendation. Furthermore, the average Bolt Projects stock price target of $2.50 per share implies a downside of over 80% from the current level.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
19 hours ago
- Business Insider
What Behind the Jaw-Dropping 556% Rally in Bolt Projects Stock (BSLK)?
Materials-solutions company Bolt Projects Holdings (BSLK) stunned the market with a jaw-dropping 550% surge in its stock price on Wednesday. The rally was fueled by exceptional Q2 2025 results and upbeat growth forecasts. Nonetheless, the stock reversed some of its gains, falling over 28% in pre-market trading on Thursday. Year-to-date, BSLK shares are still up 48.5%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What Does Bolt Projects Holdings Do? Bolt Projects is a biomaterials company that creates innovative solutions for the beauty and personal care industry. Its Vegan Silk Technology Platform creates eco-friendly silk alternatives from plant-based or bio-engineered sources rather than silkworms. Bolt Projects Reports Massive Sales Growth In Q2, Bolt Projects' revenue soared more than 2,200% year-over-year to $1.3 million. The company also narrowed its net loss to $4.6 million, a sharp improvement from the $58.9 million loss reported a year ago. Additionally, Bolt achieved a positive gross margin, posting a gross profit of $62,000 versus a $29,000 gross loss in the same quarter last year. What Lies Ahead for Bolt Projects? Bolt Projects' recent growth has been fueled largely by surging demand for its Vegan Silk Technology Platform. CEO Dan Widmaier stated that the platform offers high-performance, eco-friendly benefits that meet customer needs and set the company up for long-term growth. Bolt's Vegan Silk is already attracting interest from major beauty players. A global skincare brand, owned by one of the world's top seven beauty conglomerates, plans to launch its first product featuring Vegan Silk in 2026, with additional products already in the pipeline. Such partnerships signal a growing shift in the industry toward sustainable ingredients, where Bolt has a clear competitive advantage. Looking ahead, Bolt has, for the first time, added gross profit projections to its financial guidance. The company expects at least $500,000 in gross profit in 2025 and $1 million in 2026, alongside minimum revenue targets of $4.5 million and $9 million, respectively. If Vegan Silk adoption continues to accelerate, these numbers could mark just the beginning of Bolt's growth trajectory. Is BSLK a Good Stock to Buy? Turning to Wall Street, analysts have a Hold consensus rating on BSLK stock based on one Hold recommendation. Furthermore, the average Bolt Projects stock price target of $2.50 per share implies a downside of over 80% from the current level.
Yahoo
a day ago
- Yahoo
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +30.31%. A quarter ago, it was expected that this company would post a loss of $6.8 per share when it actually produced a loss of $5.8, delivering a surprise of +14.71%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Bolt Biotherapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 73.46%. This compares to year-ago revenues of $1.27 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Bolt Biotherapeutics shares have lost about 47.5% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for Bolt Biotherapeutics? While Bolt Biotherapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Bolt Biotherapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$5.70 on $0.9 million in revenues for the coming quarter and -$23.00 on $4.02 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the broader Zacks Medical sector, Electromed, Inc. (ELMD), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 26. This company is expected to post quarterly earnings of $0.22 per share in its upcoming report, which represents a year-over-year change of +10%. The consensus EPS estimate for the quarter has been revised 5% higher over the last 30 days to the current level. Electromed, Inc.'s revenues are expected to be $16.51 million, up 11.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bolt Biotherapeutics, Inc. (BOLT) : Free Stock Analysis Report Electromed, Inc. (ELMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
a day ago
- Yahoo
Bolt Projects Announces $4.25 Million Private Placement
Priced At-The-Market Under Nasdaq Rules BERKELEY, Calif., August 14, 2025--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (Nasdaq: BSLK) ("Bolt Projects" or the "Company"), a developer of biomaterials for the beauty and personal care industry, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 913,979 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.65 per share of common stock (or per pre-funded warrant in lieu thereof, less the nominal exercise price of $0.0001 per share) in a private placement priced at-the-market under Nasdaq rules. The private placement is expected to close on or about August 15, 2025, subject to the satisfaction of customary closing conditions. Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.25 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities issued in the private placement and shares of common stock underlying the pre-funded warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with investors, the Company has agreed to file a resale registration statement covering the securities described above. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Bolt Projects Holdings Bolt Projects develops and produces innovative biomaterials for the beauty and personal care industry. The Company is built on biomaterials platforms that aim to disrupt and transform high-volume consumer goods industries. Bolt Projects is a pioneer in the consumer biomaterials space. The Company's Vegan Silk Technology Platform produces b-silk and other offerings for the beauty and personal care industry that are fully vegan and biodegradable. These versatile ingredients have been on the market since 2019. Its intellectual property portfolio is anchored by 77 granted patents and 118 pending patent applications. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this communication, including, without limitation, statements regarding: statements related to the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of proceeds therefrom. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "budget," "continue," "could," "estimate," "expect," "forecast," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "will" or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain these words. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: market and other conditions, substantial doubt as to the Company's ability to continue as a going concern; the Company's history of net losses and negative cash flows; the Company's ability to generate sufficient cash to service its debt; the Company's ability to meet the continued listing requirements of Nasdaq and remain listed on a national stock exchange; the Company's ability to execute its business plan and adequately control its expenses or raise additional capital on favorable terms, if at all; the Company's dependence on sales of b-silk™ and xl-silk™ products from its Vegan Silk Technology Platform; the Company's reliance on a single or limited manufacturing partners and manufacturing facilities; reliance on manufacturing partners in regions that could be impacted by U.S. trade policy, including renegotiating or terminating existing trade agreements and leveraging tariffs; costs of and availability for its Vegan technology Platform products that are out of the Company's control; the Company's reliance on a single manufacturing partner and manufacturing facility for the production of its Vegan Silk Technology Platform product; pricing and availability for the Company's Vegan Silk Technology Platform products; market acceptance of from consumer product companies; the Company's ability to protect adequately its patents and other intellectual property assets; government regulations and private party actions relating to the marketing and advertising of cosmetic products that include the Company's Vegan Silk Technology Platform products or other products the Company develops; and the other risks and uncertainties discussed under the caption "Risk Factors" included in the Company's Annual Report on Form 10-K for the fiscal year ended, December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, and accessible on the SEC's website at and the Investors section of the Company's website at www. The Company cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. The Company undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. View source version on Contacts For Bolt Projects Holdings Media Inquiries: press@ For Bolt Projects Holdings Investor Inquiries: investors@
